Cargando…

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis

BACKGROUND: Treosulfan, an alkylating agent, has demonstrated activity in recurrent ovarian carcinoma. It is equieffective as oral (p.o.) and intravenous (i.v.) formulation. To explore the preference and compliance of elderly patients regarding p.o. or i.v. treosulfan for the treatment of relapsed o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahner, Sven, Oskay-Özcelik, Gülten, Heidrich-Lorsbach, Elke, Fuxius, Stefan, Sommer, Harald, Klare, Peter, Belau, Antje, Ruhmland, Birgit, Heuser, Thomas, Kölbl, Heinz, Markmann, Susanne, Sehouli, Jalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397225/
https://www.ncbi.nlm.nih.gov/pubmed/22526159
http://dx.doi.org/10.1007/s00432-012-1221-3
_version_ 1782238160583917568
author Mahner, Sven
Oskay-Özcelik, Gülten
Heidrich-Lorsbach, Elke
Fuxius, Stefan
Sommer, Harald
Klare, Peter
Belau, Antje
Ruhmland, Birgit
Heuser, Thomas
Kölbl, Heinz
Markmann, Susanne
Sehouli, Jalid
author_facet Mahner, Sven
Oskay-Özcelik, Gülten
Heidrich-Lorsbach, Elke
Fuxius, Stefan
Sommer, Harald
Klare, Peter
Belau, Antje
Ruhmland, Birgit
Heuser, Thomas
Kölbl, Heinz
Markmann, Susanne
Sehouli, Jalid
author_sort Mahner, Sven
collection PubMed
description BACKGROUND: Treosulfan, an alkylating agent, has demonstrated activity in recurrent ovarian carcinoma. It is equieffective as oral (p.o.) and intravenous (i.v.) formulation. To explore the preference and compliance of elderly patients regarding p.o. or i.v. treosulfan for the treatment of relapsed ovarian carcinoma, women aged 65 years or older were included in this prospective multicenter study. Since elderly patients usually have several concomitant diseases and experience more treatment toxicity, an interim safety analysis was planned and performed after 25 patients finished therapy to assess the tolerability of the treatment regimens. METHODS: Patients had a free choice of treosulfan i.v. (7,000 mg/m(2) day 1 of a 28-day cycle) or p.o. (600 mg/m(2) day 1–28 of a 56-day cycle) for a maximum of 12 cycles (i.v.) or 12 months (p.o.). Indecisive patients were randomized. Toxicity was evaluated according to the NCI-CTC version 2.0. RESULTS: Twenty-five of 51 recruited patients completed therapy at the time of the planned interim analysis (median age, 75 years; range, 70–82). Median ECOG was 1, and median number of prior chemotherapy regimens was 2. A median number of 4 cycles (range, 1–12) were administered per patient. Anemia was the most common hematological toxicity (88 % of patients). Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %). CONCLUSION: Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated. There were no unexpected hematological or non-hematological toxicities. Based on this safety analysis, the next step of study recruitment was continued.
format Online
Article
Text
id pubmed-3397225
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-33972252012-07-23 A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis Mahner, Sven Oskay-Özcelik, Gülten Heidrich-Lorsbach, Elke Fuxius, Stefan Sommer, Harald Klare, Peter Belau, Antje Ruhmland, Birgit Heuser, Thomas Kölbl, Heinz Markmann, Susanne Sehouli, Jalid J Cancer Res Clin Oncol Original Paper BACKGROUND: Treosulfan, an alkylating agent, has demonstrated activity in recurrent ovarian carcinoma. It is equieffective as oral (p.o.) and intravenous (i.v.) formulation. To explore the preference and compliance of elderly patients regarding p.o. or i.v. treosulfan for the treatment of relapsed ovarian carcinoma, women aged 65 years or older were included in this prospective multicenter study. Since elderly patients usually have several concomitant diseases and experience more treatment toxicity, an interim safety analysis was planned and performed after 25 patients finished therapy to assess the tolerability of the treatment regimens. METHODS: Patients had a free choice of treosulfan i.v. (7,000 mg/m(2) day 1 of a 28-day cycle) or p.o. (600 mg/m(2) day 1–28 of a 56-day cycle) for a maximum of 12 cycles (i.v.) or 12 months (p.o.). Indecisive patients were randomized. Toxicity was evaluated according to the NCI-CTC version 2.0. RESULTS: Twenty-five of 51 recruited patients completed therapy at the time of the planned interim analysis (median age, 75 years; range, 70–82). Median ECOG was 1, and median number of prior chemotherapy regimens was 2. A median number of 4 cycles (range, 1–12) were administered per patient. Anemia was the most common hematological toxicity (88 % of patients). Most frequent non-hematological toxicities were nausea (76 %), constipation (68 %), and fatigue (64 %). CONCLUSION: Treatment was generally well tolerated despite the fact that most patients suffered from multiple comorbidities and were heavily pretreated. There were no unexpected hematological or non-hematological toxicities. Based on this safety analysis, the next step of study recruitment was continued. Springer-Verlag 2012-04-15 2012 /pmc/articles/PMC3397225/ /pubmed/22526159 http://dx.doi.org/10.1007/s00432-012-1221-3 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Paper
Mahner, Sven
Oskay-Özcelik, Gülten
Heidrich-Lorsbach, Elke
Fuxius, Stefan
Sommer, Harald
Klare, Peter
Belau, Antje
Ruhmland, Birgit
Heuser, Thomas
Kölbl, Heinz
Markmann, Susanne
Sehouli, Jalid
A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
title A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
title_full A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
title_fullStr A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
title_full_unstemmed A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
title_short A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
title_sort prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397225/
https://www.ncbi.nlm.nih.gov/pubmed/22526159
http://dx.doi.org/10.1007/s00432-012-1221-3
work_keys_str_mv AT mahnersven aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT oskayozcelikgulten aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT heidrichlorsbachelke aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT fuxiusstefan aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT sommerharald aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT klarepeter aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT belauantje aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT ruhmlandbirgit aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT heuserthomas aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT kolblheinz aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT markmannsusanne aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT sehoulijalid aprospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT mahnersven prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT oskayozcelikgulten prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT heidrichlorsbachelke prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT fuxiusstefan prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT sommerharald prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT klarepeter prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT belauantje prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT ruhmlandbirgit prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT heuserthomas prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT kolblheinz prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT markmannsusanne prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis
AT sehoulijalid prospectivemulticenterstudyoftreosulfaninelderlypatientswithrecurrentovariancancerresultsofaplannedsafetyanalysis